There are still no effective treatments to prevent, halt, or reverse Alzheimer's disease, but
research advances over the past three decades could change this gloomy picture. Genetic …

Alzheimer's disease (AD) is the most common cause of memory impairment and dementia in
the elderly. AD is pathologically characterized by extracellular deposits of beta-amyloid (Aβ) …

Background Amyloid-related imaging abnormalities (ARIA) have been reported in patients
with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody …

Background Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical
development for the treatment of Alzheimer disease (AD). Objectives To investigate whether …

Aβ Immunotherapy is a promising therapeutic approach for Alzheimer's disease. Preclinical
studies demonstrate that plaque prevention is possible; however, the more relevant …

Alzheimer disease (AD) is one of, if not the most, feared diseases associated with aging. The
prevalence of AD increases exponentially with age after 60 years. Increasing life expectancy …

Background Given the slow and variable clinical course of Alzheimer disease, very large
and extended clinical trials are needed to identify a beneficial clinical effect of disease …

J. Neurochem.(2012) 120 (Suppl. 1), 186–193. Abstract Recent advances in the
understanding of Alzheimer's disease pathogenesis have led to the development of …

The prevalence of microbleeds on magnetic resonance imaging (MRI) in patients with
Alzheimer's disease (AD) is lower than that of its presumed pathological correlate, cerebral …

As the societal and economic burdens of Alzheimer′ s disease (AD) continue to mount, so
does the need for therapies that slow the progression of the illness. Beta amyloid has long …